文献速递乳腺癌

HER2阳性乳腺癌试验中静脉帕妥珠单抗联合曲妥珠单抗或固定剂量皮下复方制剂过敏反应与超敏反应的发生率和严重程度

Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer.
PubMed 文献 · Eur J Cancer · 2022-10-07

该分析汇总了支持欧洲药品管理局产品特征摘要的9项关键试验,纳入4772例接受静脉帕妥珠单抗联合曲妥珠单抗(PH IV)和/或固定剂量皮下复方制剂(PH FDC SC)的患者,刻画过敏反应/超敏反应风险。结果显示PH IV的各级事件发生率为3-11%(≥3级≤2%),PH FDC SC为2-3%(<1%且与PH FDC SC无关),多数事件发生在同步化疗的前6-8个周期。结论认为PH IV和PH FDC SC耐受性良好。

要点

  • 静脉PH方案各级过敏/超敏反应发生率3-11%,≥3级≤2%,因事件停药一般<1%。
  • 皮下固定剂量复方制剂各级事件发生率2-3%,<1%且与PH FDC SC无关,尚无因事件停药记录。
  • 多数事件发生在同步化疗的前6-8个周期,后续周期减少(MetaPHER除外)。

核心结论

  • PH IV和PH FDC SC耐受性良好,PH IV报告的≥3级过敏/超敏反应事件很少,PH FDC SC无≥3级相关事件。
  • 大多数事件发生在化疗期间。

研究设计与样本

  • 对现行EMA产品特征摘要中引用的全部关键试验进行过敏反应/超敏反应(罗氏标准不良事件组术语)的累积检索。
  • 纳入转移性乳腺癌试验NCT00567190、NCT02402712和早期乳腺癌试验NCT01358877、NCT00545688、NCT00976989、NCT02132949、NCT03493854、NCT03674112。
  • 分析共纳入4772例接受PH IV和/或PH FDC SC的患者。
  • 分析事件的发生、发生率和严重程度,并按周期进行时间趋势分析。

主要发现

  • PH IV转移性乳腺癌试验中各级(≥3级)过敏/超敏反应发生率为3-11%(≤2%)。
  • PH IV早期乳腺癌试验中各级(≥3级)发生率为1-13%(0-3%)。
  • PH FDC SC早期乳腺癌试验中各级(≥3级)发生率为2-3%(<1%,且与PH FDC SC无关)。
  • PH IV因过敏/超敏反应停药少见,一般<1%,但TRYPHAENA两个组分别为1%和3%;PH FDC SC迄今无停药记录。
  • 时间趋势分析显示多数事件发生在同步化疗的前6-8个周期,后续周期减少(MetaPHER除外)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To characterise risk of anaphylaxis/hypersensitivity with intravenous pertuzumab plus trastuzumab (PH IV), the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) or concomitant chemotherapy to support potential administration of PH FDC SC by healthcare professionals outside clinics. METHODS: A cumulative search for anaphylaxis/hypersensitivity (Roche Standard Adverse Event Group Terms) was performed for all pivotal trials cited in the current EMA P IV/PH FDC SC summaries of product characteristics: MBC: NCT00567190, NCT02402712; EBC: NCT01358877, NCT00545688, NCT00976989, NCT02132949, NCT03493854 and NCT03674112. Occurrence, incidence and severity of events were analysed and a time-trend analysis (by cycle) was performed. RESULTS: This analysis includes 4772 patients who received PH IV and/or PH FDC SC. Incidence of all-grade (grade ≥3) anaphylaxis/hypersensitivity events: 3-11% (≤2%) for PH IV MBC trials; 1-13% (0-3%) for PH IV EBC trials; and 2-3% (<1%; not related to PH FDC SC) for PH FDC SC EBC trials. Discontinuations due to anaphylaxis/hypersensitivity were rare for PH IV (generally <1% except two arms of TRYPHAENA: 1% and 3%); no discontinuations of PH FDC SC have been recorded so far. Time-trend analysis showed that most events were reported during the first 6-8 cycles with concurrent chemotherapy, with a decrease in later cycles (except MetaPHER). CONCLUSION: PH IV and PH FDC SC were well tolerated, with few grade ≥3 anaphylaxis/hypersensitivity events reported with PH IV and no grade ≥3 related events with PH FDC SC. Most events occurred during chemotherapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Swain SM, Tan AR, Gianni L, et al. Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer. Eur J Cancer. 2022. PMID: 36410207. doi:10.1016/j.ejca.2022.09.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。